{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:59:30Z","timestamp":1776157170172,"version":"3.50.1"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA037820"],"award-info":[{"award-number":["DA037820"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA037820"],"award-info":[{"award-number":["DA037820"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA054190"],"award-info":[{"award-number":["DA054190"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA037820"],"award-info":[{"award-number":["DA037820"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Co-use of methamphetamine (MA) and opioids (pharmaceutical pills, heroin and fentanyls) has increased in the United States and is represented in rising mortality. Although coinciding with the import of low cost, high potency and purity methamphetamine, the relationship between supply and demand in propelling this polydrug use is not well understood. We consider the influence of macro changes in supply on the uptake of opioid and methamphetamine co-use by injection at the level of individual drug and injection initiation in West Virginia, a state which leads the US in drug overdose mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>We recruited n\u2009=\u200930 people for semi-structured interviews who self-reported injecting heroin\/fentanyl and using methamphetamine by any route at a West Virginia syringe service program and through snowball sampling. Interviews were recorded and transcripts analyzed using a thematic approach. Ethnographic observation was also conducted and recorded in fieldnotes. Sequence of substance and mode of use initiation and use trajectories for opioids and stimulants were charted for each participant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A clear pattern of individual drug initiation emerged that matched each successive supply wave of the US overdose epidemic: 25 participants had initiated opioid use with pills, followed by heroin, often mixed with\/replaced by fentanyl, and subsequently added methamphetamine use. For participants, the supply and consumption of opioid analgesics had set in motion a series of steps leading to the addition of stimulant injection to existing opioid injecting repertoires. Unlike other studies that have found a birth cohort effect in patterns of initiation, participants showed the same sequence across age groups. Considerations of economy, availability, dependence, tolerance and the erosion of taboos that marked transitions from opioid pills to heroin injection influenced these subsequent trajectories in novel ways. The form, timing and extent of opioid and stimulant consumption was influenced by four stages of the changing drug supply, which in turn reflected back on demand.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Transformations in the social meaning and supply of methamphetamine enabled these transitions while other desired, non-injectable drugs were difficult to obtain. We discuss policy implications of injectable drugs\u2019 market dominance at this location and possible interventions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-00976-1","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T09:02:39Z","timestamp":1709629359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The influence of transformations in supply on methamphetamine initiation among people injecting opioids in the United States"],"prefix":"10.1186","volume":"21","author":[{"given":"Sarah","family":"Mars","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Ondocsin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Holm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Ciccarone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"976_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4159\/9780674029903","volume-title":"Forces of habit: drugs and the making of the modern world","author":"DT Courtwright","year":"2001","unstructured":"Courtwright DT. Forces of habit: drugs and the making of the modern world. Cambridge: Harvard University Press; 2001. p. 277."},{"key":"976_CR2","unstructured":"Royal College of Psychiatrists in Drugs: Dilemmas and choices. 2000, Gaskell: London. p 185\u2013213"},{"issue":"3","key":"976_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1360-0443.2006.01694.x","volume":"102","author":"T Fowler","year":"2007","unstructured":"Fowler T, et al. Exploring the relationship between genetic and environmental influences on initiation and progression of substance use. Addiction. 2007;102(3):413\u201322.","journal-title":"Addiction"},{"issue":"3","key":"976_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1360-0443.2009.02831.x","volume":"105","author":"KJ Verweij","year":"2010","unstructured":"Verweij KJ, et al. Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies. Addiction. 2010;105(3):417\u201330.","journal-title":"Addiction"},{"key":"976_CR5","volume-title":"The forgotten success story: Japan and the methamphetamine problem","author":"B Edstr\u00f6m","year":"2015","unstructured":"Edstr\u00f6m B. The forgotten success story: Japan and the methamphetamine problem. UK: Taylor and Francis; 2015."},{"issue":"2","key":"976_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1360-0443.1987.tb01453.x","volume":"82","author":"H Parker","year":"1987","unstructured":"Parker H, Newcombe R, Bakx K. The new heroin users: prevalence and characteristics in Wirral. Merseyside British Journal of Addiction. 1987;82(2):147\u201357.","journal-title":"Merseyside British Journal of Addiction"},{"issue":"6408","key":"976_CR7","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1126\/science.aau1184","volume":"361","author":"H Jalal","year":"2018","unstructured":"Jalal H, et al. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science. 2018;361(6408):1184.","journal-title":"Science"},{"key":"976_CR8","unstructured":"Centers for Disease Control and Prevention, N.C.f.I.P.a.C. The Drug Overdose Epidemic: Behind the Numbers. Opioids 2022 [cited 2022 08\/26\/22]; Available from: https:\/\/www.cdc.gov\/opioids\/data\/index.html"},{"key":"976_CR9","doi-asserted-by":"crossref","unstructured":"Hedegaard, H., et al., Drug overdose deaths in the United States, 1999\u20132020. NCHS data brief, 2022(428)","DOI":"10.15620\/cdc:112340"},{"issue":"4","key":"976_CR10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344\u201350.","journal-title":"Curr Opin Psychiatry"},{"issue":"2","key":"976_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2105\/AJPH.2017.304187","volume":"108","author":"N Dasgupta","year":"2018","unstructured":"Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. Am J Public Health. 2018;108(2):182\u20136.","journal-title":"Am J Public Health"},{"issue":"5","key":"976_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.amepre.2018.01.040","volume":"54","author":"SM Monnat","year":"2018","unstructured":"Monnat SM. Factors associated with county-level differences in U.S. drug-related mortality rates. Am J Prev Med. 2018;54(5):611\u20139.","journal-title":"Am J Prev Med"},{"issue":"2","key":"976_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugpo.2013.10.004","volume":"25","author":"SG Mars","year":"2014","unstructured":"Mars SG, et al. \u201cEvery \u2018never\u2019 I ever said came true\u201d: transitions from opioid pills to heroin injecting. Int J Drug Policy. 2014;25(2):257\u201366.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"976_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.drugpo.2011.05.014","volume":"23","author":"SE Lankenau","year":"2012","unstructured":"Lankenau SE, et al. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2012;23(1):37\u201344.","journal-title":"Int J Drug Policy"},{"key":"976_CR15","unstructured":"Cicero TJ, Ellis MS The prescription opioid epidemic: a review of qualitative studies on the progression from initial use to abuse. Dialogues in clinical neuroscience, 2022"},{"key":"976_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","volume":"71","author":"D Ciccarone","year":"2019","unstructured":"Ciccarone D. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183\u20138.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"976_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1056\/NEJMc1204141","volume":"367","author":"TJ Cicero","year":"2012","unstructured":"Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367(2):187\u20139.","journal-title":"N Engl J Med"},{"key":"976_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.drugpo.2015.12.021","volume":"28","author":"A Harocopos","year":"2016","unstructured":"Harocopos A, Allen B, Paone D. Circumstances and contexts of heroin initiation following non-medical opioid analgesic use in New York City. I J Drug Policy. 2016;28:106\u201312.","journal-title":"I J Drug Policy"},{"issue":"2","key":"976_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2105\/AJPH.2015.302972","volume":"106","author":"SP Novak","year":"2016","unstructured":"Novak SP, et al. Initiation of heroin and prescription opioid pain relievers by birth cohort. Am J Public Health. 2016;106(2):298\u2013300.","journal-title":"Am J Public Health"},{"key":"976_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.drugpo.2017.06.004","volume":"46","author":"D Ciccarone","year":"2017","unstructured":"Ciccarone D, Ondocsin J, Mars SG. Heroin uncertainties: Exploring users\u2019 perceptions of fentanyl-adulterated and -substituted \u201cheroin.\u201d Int J Drug Policy. 2017;46:146\u201355.","journal-title":"Int J Drug Policy"},{"issue":"10","key":"976_CR21","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1001\/jamainternmed.2016.4310","volume":"176","author":"TC Green","year":"2016","unstructured":"Green TC, Gilbert M. Counterfeit medications and fentanyl. JAMA Intern Med. 2016;176(10):1555\u20137.","journal-title":"JAMA Intern Med"},{"key":"976_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109398","volume":"234","author":"JJ Palamar","year":"2022","unstructured":"Palamar JJ, et al. Trends in seizures of powders and pills containing illicit fentanyl in the United States, 2018 through 2021. Drug Alcohol Depend. 2022;234: 109398.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"976_CR23","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/add.14474","volume":"114","author":"SG Mars","year":"2019","unstructured":"Mars SG, Rosenblum D, Ciccarone D. Illicit fentanyls in the opioid street market: desired or imposed? Addiction. 2019;114(5):774\u201380.","journal-title":"Addiction"},{"key":"976_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.drugpo.2017.05.023","volume":"46","author":"JJ Carroll","year":"2017","unstructured":"Carroll JJ, et al. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: a mixed methods study. I J Drug Policy. 2017;46:136\u201345.","journal-title":"I J Drug Policy"},{"key":"976_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109003","volume":"227","author":"AH Kral","year":"2021","unstructured":"Kral AH, et al. Transition from injecting opioids to smoking fentanyl in San Francisco. California Drug Alcohol Depend. 2021;227: 109003.","journal-title":"California Drug Alcohol Depend"},{"key":"976_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.drugpo.2019.05.020","volume":"71","author":"R Daniulaityte","year":"2019","unstructured":"Daniulaityte R, et al. Street fentanyl use: Experiences, preferences, and concordance between self-reports and urine toxicology. Int J Drug Policy. 2019;71:3\u20139.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"976_CR27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1177\/1073110518782937","volume":"46","author":"RL Rothberg","year":"2018","unstructured":"Rothberg RL, Stith K. Fentanyl: a whole New World? J Law Med Ethics. 2018;46(2):314\u201324.","journal-title":"J Law Med Ethics"},{"key":"976_CR28","unstructured":"Drug Enforcement Administration, National Drug Threat Assessment. 2019, Department of Justice"},{"key":"976_CR29","unstructured":"US Drug Enforcement Administration, Fentanyl Flow to the United States, DEA Intelligence Brief. (2020)"},{"issue":"4","key":"976_CR30","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.3390\/ijerph19042074","volume":"19","author":"C Wang","year":"2022","unstructured":"Wang C, et al. The evolving regulatory landscape for fentanyl: China, India, and global drug Governance. Int J Environ Res Public Health. 2022;19(4):2074.","journal-title":"Int J Environ Res Public Health"},{"key":"976_CR31","unstructured":"U.S. Customs and Border Protection. Drug Seizure Statistics. 2024 02\/13\/2024 [cited 2024 February 22]; Available from: https:\/\/www.cbp.gov\/newsroom\/stats\/drug-seizure-statistics"},{"key":"976_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.drugalcdep.2017.10.011","volume":"182","author":"SN Glick","year":"2018","unstructured":"Glick SN, et al. Increasing methamphetamine injection among non-MSM who inject drugs in King County. Washington Drug Alcohol Depend. 2018;182:86\u201392.","journal-title":"Washington Drug Alcohol Depend"},{"key":"976_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","volume":"193","author":"MS Ellis","year":"2018","unstructured":"Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14\u201320.","journal-title":"Drug Alcohol Depend"},{"key":"976_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108089","volume":"213","author":"JJ Palamar","year":"2020","unstructured":"Palamar JJ, Han BH, Keyes KM. Trends in characteristics of individuals who use methamphetamine in the United States, 2015\u20132018. Drug Alcohol Depend. 2020;213: 108089.","journal-title":"Drug Alcohol Depend"},{"key":"976_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103463","volume":"99","author":"R Daniulaityte","year":"2022","unstructured":"Daniulaityte R, et al. Lay knowledge and practices of methamphetamine use to manage opioid-related overdose risks. Int J Drug Policy. 2022;99: 103463.","journal-title":"Int J Drug Policy"},{"issue":"11","key":"976_CR36","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1080\/10826084.2021.1949612","volume":"56","author":"SM Silverstein","year":"2021","unstructured":"Silverstein SM, et al. \u201cIt\u2019s crazy what meth can help you do\u201d: lay beliefs, practices, and experiences of using methamphetamine to self-treat symptoms of opioid withdrawal. Subst Use Misuse. 2021;56(11):1687\u201396.","journal-title":"Subst Use Misuse"},{"key":"976_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.103098","volume":"91","author":"AM Lopez","year":"2021","unstructured":"Lopez AM, et al. Co-use of methamphetamine and opioids among people in treatment in Oregon: a qualitative examination of interrelated structural, community, and individual-level factors. Int J Drug Policy. 2021;91: 103098.","journal-title":"Int J Drug Policy"},{"key":"976_CR38","doi-asserted-by":"publisher","first-page":"103467","DOI":"10.1016\/j.drugpo.2021.103467","volume":"99","author":"SE Duhart Clarke","year":"2022","unstructured":"Duhart Clarke SE, Kral AH, Zibbell JE. Consuming illicit opioids during a drug overdose epidemic: Illicit fentanyls, drug discernment, and the radical transformation of the illicit opioid market. Int J Drug Policy. 2022;99:103467.","journal-title":"Int J Drug Policy"},{"key":"976_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103791","volume":"107","author":"A Ivsins","year":"2022","unstructured":"Ivsins A, et al. The practice and embodiment of \u201cgoofballs\u201d: a qualitative study exploring the co-injection of methamphetamines and opioids. Int J Drug Policy. 2022;107: 103791.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"976_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/ADM.0000000000000669","volume":"15","author":"R Baker","year":"2021","unstructured":"Baker R, et al. \u201cLike Yin and Yang\u201d: perceptions of methamphetamine benefits and consequences among people who use opioids in rural communities. J Addict Med. 2021;15(1):34\u20139.","journal-title":"J Addict Med"},{"issue":"1","key":"976_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-023-00816-8","volume":"20","author":"J Ondocsin","year":"2023","unstructured":"Ondocsin J, Holm N, Mars SG, Ciccarone D. The Motives and Methods of Methamphetamine and \u2018Heroin\u2019 Co-Use in West Virginia Under peer review. Harm Reduct J. 2023;20(1):88.","journal-title":"Harm Reduct J"},{"issue":"1","key":"976_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/15332640.2017.1325809","volume":"18","author":"KC Flynn","year":"2019","unstructured":"Flynn KC, Hoffer LD. Transitioning illicit drug preferences and emerging user identities in Ohio: the proliferation of methamphetamine use among African Americans. J Ethn Subst Abuse. 2019;18(1):67\u201388.","journal-title":"J Ethn Subst Abuse"},{"issue":"3","key":"976_CR43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.drugalcdep.2005.04.012","volume":"80","author":"KC Ochoa","year":"2005","unstructured":"Ochoa KC, et al. Heroin overdose among young injection drug users in San Francisco. Drug Alcohol Depend. 2005;80(3):297\u2013302.","journal-title":"Drug Alcohol Depend"},{"key":"976_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","volume":"171","author":"J Suzuki","year":"2017","unstructured":"Suzuki J, El-Haddad S. A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend. 2017;171:107\u201316.","journal-title":"Drug Alcohol Depend"},{"key":"976_CR45","unstructured":"Drug Enforcement Administration, 2018 National Drug Threat Assessment, D.o. Justice, Editor. 2018"},{"issue":"3","key":"976_CR46","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/dta.3186","volume":"14","author":"SG Toske","year":"2022","unstructured":"Toske SG, McKibben TD. Monitoring methamphetamine in the United States: a two-decade review as seen by the DEA methamphetamine profiling program. Drug Test Anal. 2022;14(3):416\u201326.","journal-title":"Drug Test Anal"},{"issue":"3","key":"976_CR47","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1360-0443.2008.02458.x","volume":"104","author":"JK Cunningham","year":"2009","unstructured":"Cunningham JK, Liu L-M, Callaghan R. Impact of US and Canadian precursor regulation on methamphetamine purity in the United States. Addiction. 2009;104(3):441\u201353.","journal-title":"Addiction"},{"issue":"1","key":"976_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/19492901.2013.11728384","volume":"5","author":"W Garriott","year":"2013","unstructured":"Garriott W. Methamphetamine in rural America: notes on Its emergence. Anthropology Now. 2013;5(1):27\u201335.","journal-title":"Anthropology Now"},{"issue":"7","key":"976_CR49","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/j.1360-0443.2008.02208.x","volume":"103","author":"JK Cunningham","year":"2008","unstructured":"Cunningham JK, Liu LM, Muramoto M. Methamphetamine suppression and route of administration: precursor regulation impacts on snorting, smoking, swallowing and injecting. Addiction. 2008;103(7):1174\u201386.","journal-title":"Addiction"},{"key":"976_CR50","unstructured":"US Drug Enforcement Administration, National Drug Threat Assessment Summary, D.o. Justice, Editor. 2016. p 80\u201381"},{"key":"976_CR51","unstructured":"Drug Enforcement Administration, National Drug Threat Assessment. 2018, Department of Justice"},{"issue":"4","key":"976_CR52","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/09595239700186711","volume":"16","author":"J Strang","year":"1997","unstructured":"Strang J, Griffiths P, Gossop M. Heroin in the United Kingdom: different forms, different origins, and the relationship to different routes of administration. Drug Alcohol Rev. 1997;16(4):329\u201337.","journal-title":"Drug Alcohol Rev"},{"issue":"12","key":"976_CR53","doi-asserted-by":"publisher","first-page":"317","DOI":"10.15585\/mmwr.mm6912a1","volume":"69","author":"CM Jones","year":"2020","unstructured":"Jones CM, Compton WM, Mustaquim D. Patterns and characteristics of methamphetamine use among adults\u2014United States, 2015\u20132018. Morb Mortal Wkly Rep. 2020;69(12):317.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"14","key":"976_CR54","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1081\/JA-120025125","volume":"38","author":"D Ciccarone","year":"2003","unstructured":"Ciccarone D, Bourgois P. Explaining the geographical variation of HIV among injection drug users in the United States. Subst Use Misuse. 2003;38(14):2049\u201363.","journal-title":"Subst Use Misuse"},{"issue":"3","key":"976_CR55","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.drugpo.2008.08.003","volume":"20","author":"D Ciccarone","year":"2009","unstructured":"Ciccarone D. Heroin in brown, black and white: structural factors and medical consequences in the US heroin market. Int J Drug Policy. 2009;20(3):277\u201382.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"976_CR56","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/archpsyc.1975.01760250115013","volume":"32","author":"D Kandel","year":"1975","unstructured":"Kandel D, Faust R. Sequence and stages in patterns of adolescent drug use. Arch Gen Psychiatry. 1975;32(7):923\u201332.","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"976_CR57","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2105\/AJPH.74.7.668","volume":"74","author":"K Yamaguchi","year":"1984","unstructured":"Yamaguchi K, Kandel DB. Patterns of drug use from adolescence to young adulthood: II. Sequences of progression. Am J Public Health. 1984;74(7):668\u201372.","journal-title":"Am J Public Health"},{"issue":"12","key":"976_CR58","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1046\/j.1360-0443.2002.00280.x","volume":"97","author":"AR Morral","year":"2002","unstructured":"Morral AR, McCaffrey DF, Paddock SM. Reassessing the marijuana gateway effect. Addiction. 2002;97(12):1493\u2013504.","journal-title":"Addiction"},{"issue":"3","key":"976_CR59","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/0022146510378238","volume":"51","author":"K Van Gundy","year":"2010","unstructured":"Van Gundy K, Rebellon CJ. A life-course perspective on the \u201cgateway hypothesis.\u201d J Health Soc Behav. 2010;51(3):244\u201359.","journal-title":"J Health Soc Behav"},{"issue":"3","key":"976_CR60","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/0022042613475599","volume":"43","author":"A Golub","year":"2013","unstructured":"Golub A, Brownstein HH. Drug generations in the 2000s: an analysis of arrestee data. Journal of Drug Issues. 2013;43(3):335\u201356.","journal-title":"Journal of Drug Issues"},{"issue":"51\u201352","key":"976_CR61","first-page":"1419","volume":"67","author":"L Scholl","year":"2019","unstructured":"Scholl L, et al. Drug and opioid-involved overdose deaths\u2014United States, 2013\u20132017. Morb Mortal Wkly Rep. 2019;67(51\u201352):1419.","journal-title":"Morb Mortal Wkly Rep"},{"key":"976_CR62","unstructured":"West Virginia Department of Health and Human Resources, West Virginia drug overdose deaths historical overview 2001\u20132015. 2017: Charleston, WV. p 25"},{"issue":"1","key":"976_CR63","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12954-020-00416-w","volume":"17","author":"J Ondocsin","year":"2020","unstructured":"Ondocsin J, et al. Hostility, compassion and role reversal in West Virginia\u2019s long opioid overdose emergency. Harm Reduct J. 2020;17(1):74.","journal-title":"Harm Reduct J"},{"issue":"7","key":"976_CR64","first-page":"127","volume":"7","author":"JA Inciardi","year":"2007","unstructured":"Inciardi JA, et al. The diversion of prescription opioid analgesics. Law Enforc Exec Forum. 2007;7(7):127\u201341.","journal-title":"Law Enforc Exec Forum"},{"key":"976_CR65","unstructured":"O'Leary, S. Income Inequality at Historic High in West Virginia 2013; Available from: https:\/\/wvpolicy.org\/income-inequality-at-historic-high-in-wv\/"},{"issue":"2","key":"976_CR66","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11013-022-09769-2","volume":"47","author":"SG Mars","year":"2022","unstructured":"Mars SG, et al. \u2018The High Five Club\u2019: social relations and perspectives on HIV-Related Stigma During an HIV Outbreak in West Virginia. Cult Med Psychiatry. 2022;47(2):329\u201349.","journal-title":"Cult Med Psychiatry"},{"key":"976_CR67","doi-asserted-by":"crossref","unstructured":"Fessel JN, et al, Into the Epistemic Void: Using Rapid Assessment to Investigate the Opioid Crisis. Inside Ethnography: Researchers Reflect on the Challenges of Reaching Hidden Populations, 2019: p 120","DOI":"10.2307\/j.ctvqmp20g.11"},{"issue":"8","key":"976_CR68","doi-asserted-by":"publisher","first-page":"e1001863","DOI":"10.1371\/journal.pmed.1001863","volume":"12","author":"K Christopoulos","year":"2015","unstructured":"Christopoulos K, Olender S, Lopez AM, Lekas H-M, Jaiswal J, Mellman W, Geng E, Koester KA. Retained in HIV care but not on antiretroviral treatment: a qualitative patient-provider dyadic study. PLoS Med. 2015;12(8):e1001863.","journal-title":"PLoS Med"},{"key":"976_CR69","doi-asserted-by":"publisher","DOI":"10.4324\/9780203793206","volume-title":"Discovery of grounded theory: Strategies for qualitative research","author":"BG Glaser","year":"2017","unstructured":"Glaser BG, Strauss AL. Discovery of grounded theory: Strategies for qualitative research. Routledge; 2017."},{"key":"976_CR70","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.drugalcdep.2015.02.011","volume":"149","author":"RN Bluthenthal","year":"2015","unstructured":"Bluthenthal RN, et al. Factors associated with being asked to initiate someone into injection drug use. Drug Alcohol Depend. 2015;149:252\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"976_CR71","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.drugalcdep.2018.01.005","volume":"185","author":"RN Bluthenthal","year":"2018","unstructured":"Bluthenthal RN, Wenger LD, Bourgois P, Valente T, Kral AH. Differences in time to injection onset by drug in California: implications for the emerging heroin epidemic. Drug Alcohol Depend. 2018;185:253\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"976_CR72","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/10550887.2011.581989","volume":"30","author":"SP Novak","year":"2011","unstructured":"Novak SP, Kral AH. Comparing injection and non-injection routes of administration for heroin, methamphetamine, and cocaine users in the United States. J Addict Dis. 2011;30(3):248\u201357.","journal-title":"J Addict Dis"},{"issue":"8","key":"976_CR73","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1046\/j.1360-0443.1996.918118710.x","volume":"91","author":"N Crofts","year":"1996","unstructured":"Crofts N, et al. The first hit: circumstances surrounding initiation into injecting. Addiction. 1996;91(8):1187\u201396.","journal-title":"Addiction"},{"issue":"4","key":"976_CR74","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/aas.12281","volume":"58","author":"K Svendsen","year":"2014","unstructured":"Svendsen K, et al. Persistent opioid use and socio-economic factors: A population-based study in N orway. Acta Anaesthesiol Scand. 2014;58(4):437\u201345.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"6","key":"976_CR75","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1016\/j.amepre.2007.02.006","volume":"32","author":"CT Williams","year":"2007","unstructured":"Williams CT, Latkin CA. Neighborhood socioeconomic status, personal network attributes, and use of heroin and cocaine. Am J Prev Med. 2007;32(6):S203\u201310.","journal-title":"Am J Prev Med"},{"issue":"5","key":"976_CR76","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1467-9566.2007.01016.x","volume":"29","author":"J Payne","year":"2007","unstructured":"Payne J. Women drug users in North Cumbria: what influences initiation into heroin in this non-urban setting? Sociol Health Illn. 2007;29(5):633\u201355.","journal-title":"Sociol Health Illn"},{"issue":"12","key":"976_CR77","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1111\/add.13957","volume":"112","author":"A Guise","year":"2017","unstructured":"Guise A, et al. The experience of initiating injection drug use and its social context: a qualitative systematic review and thematic synthesis. Addiction. 2017;112(12):2098\u2013111.","journal-title":"Addiction"},{"key":"976_CR78","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.drugpo.2015.10.006","volume":"30","author":"AL Hobkirk","year":"2016","unstructured":"Hobkirk AL, et al. A qualitative study of methamphetamine initiation in Cape Town, South Africa. Int J Drug Policy. 2016;30:99\u2013106.","journal-title":"Int J Drug Policy"},{"issue":"26","key":"976_CR79","doi-asserted-by":"publisher","first-page":"697","DOI":"10.15585\/mmwr.mm6626a4","volume":"66","author":"GP Guy Jr","year":"2017","unstructured":"Guy GP Jr, et al. Vital signs: changes in opioid prescribing in the United States, 2006\u20132015. MMWR Morb Mortal Wkly Rep. 2017;66(26):697\u2013704.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"976_CR80","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jamainternmed.2018.6989","volume":"179","author":"GP Guy Jr","year":"2019","unstructured":"Guy GP Jr, et al. County-level opioid prescribing in the United States, 2015 and 2017. JAMA Intern Med. 2019;179(4):574\u20136.","journal-title":"JAMA Intern Med"},{"issue":"11","key":"976_CR81","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2105\/AJPH.2017.304059","volume":"107","author":"MD Livingston","year":"2017","unstructured":"Livingston MD, et al. Recreational cannabis legalization and opioid-related deaths in colorado, 2000\u20132015. Am J Public Health. 2017;107(11):1827\u20139.","journal-title":"Am J Public Health"},{"issue":"2","key":"976_CR82","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/ecin.12819","volume":"58","author":"NW Chan","year":"2020","unstructured":"Chan NW, Burkhardt J, Flyr M. The effects of recreational marijuana legalization and dispensing on opioid mortality. Econ Inq. 2020;58(2):589\u2013606.","journal-title":"Econ Inq"},{"issue":"7","key":"976_CR83","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/add.13941","volume":"113","author":"W Hall","year":"2018","unstructured":"Hall W. The future of the international drug control system and national drug prohibitions. Addiction. 2018;113(7):1210\u201323.","journal-title":"Addiction"},{"issue":"7","key":"976_CR84","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1001\/jama.2019.0077","volume":"321","author":"K Humphreys","year":"2019","unstructured":"Humphreys K, Saitz R. Should physicians recommend replacing opioids with cannabis? JAMA. 2019;321(7):639\u201340.","journal-title":"JAMA"},{"key":"976_CR85","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bpobgyn.2022.07.002","volume":"85","author":"NL Eichorn","year":"2022","unstructured":"Eichorn NL, et al. Making a joint decision: Cannabis as a potential substitute for opioids in obstetrics and gynecology. Best Pract Res Clin Obstetr Gynaecol. 2022;85:59\u201367.","journal-title":"Best Pract Res Clin Obstetr Gynaecol"},{"issue":"3","key":"976_CR86","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/002204260903900308","volume":"39","author":"M Wouters","year":"2009","unstructured":"Wouters M, Korf DJ. Access to licensed cannabis supply and the separation of markets policy in the Netherlands. J Drug Issues. 2009;39(3):627\u201351.","journal-title":"J Drug Issues"},{"issue":"2","key":"976_CR87","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1192\/bjp.178.2.123","volume":"178","author":"R MacCoun","year":"2001","unstructured":"MacCoun R, Reuter P. Evaluating alternative cannabis regimes. Br J Psychiatry. 2001;178(2):123\u20138.","journal-title":"Br J Psychiatry"},{"key":"976_CR88","unstructured":"Bates C, Rowell A, Tobacco Explained... The truth about the tobacco industry... in its own words. 2004"},{"issue":"2","key":"976_CR89","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2105\/AJPH.2007.131714","volume":"99","author":"A Van Zee","year":"2009","unstructured":"Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221\u20137.","journal-title":"Am J Public Health"},{"key":"976_CR90","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.drugpo.2019.10.008","volume":"74","author":"R Room","year":"2019","unstructured":"Room R, \u00d6rnberg JC. Government monopoly as an instrument for public health and welfare: lessons for cannabis from experience with alcohol monopolies. Int J Drug Policy. 2019;74:223\u20138.","journal-title":"Int J Drug Policy"},{"key":"976_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104157","volume":"120","author":"M Karamouzian","year":"2023","unstructured":"Karamouzian M, et al. Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: a qualitative analysis. Int J Drug Policy. 2023;120: 104157.","journal-title":"Int J Drug Policy"},{"key":"976_CR92","volume-title":"Heroin addiction: Treatment and control in Britain","author":"GV Stimson","year":"1982","unstructured":"Stimson GV, Oppenheimer E. Heroin addiction: Treatment and control in Britain. Routledge; 1982."},{"issue":"4","key":"976_CR93","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000259173","volume":"3","author":"A Uchtenhagen","year":"1997","unstructured":"Uchtenhagen A, et al. Programme for a medical prescription of narcoticsa synthesis of results. Eur Addict Res. 1997;3(4):160\u20133.","journal-title":"Eur Addict Res"},{"issue":"S2","key":"976_CR94","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.2105\/AJPH.2021.306692","volume":"112","author":"R McNeil","year":"2022","unstructured":"McNeil R, et al. Implementation of safe supply alternatives during intersecting COVID-19 and overdose health emergencies in British Columbia, Canada, 2021. Am J Public Health. 2022;112(S2):S151\u20138.","journal-title":"Am J Public Health"},{"key":"976_CR95","unstructured":"Mars SG, The Politics of Addiction. Medical Conflict and Drug Dependence in England since the 1960s. First published, 2012 ed. Science, Technology and Medicine in Modern History, ed. J. Pickstone. 2021 (paperback edition), Houndsmill and New York: Springer"},{"key":"976_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109740","volume":"243","author":"HJ Elder","year":"2023","unstructured":"Elder HJ, et al. Amphetamines modulate fentanyl-depressed respiration in a bidirectional manner. Drug Alcohol Depend. 2023;243: 109740.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"976_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-021-00266-2","volume":"16","author":"MC Frost","year":"2021","unstructured":"Frost MC, et al. The impact of methamphetamine\/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review. Addict Sci Clin Pract. 2021;16(1):1\u201325.","journal-title":"Addict Sci Clin Pract"},{"key":"976_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108307","volume":"216","author":"HD Brown","year":"2020","unstructured":"Brown HD, DeFulio A. Contingency management for the treatment of methamphetamine use disorder: a systematic review. Drug Alcohol Depend. 2020;216: 108307.","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"976_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002715","volume":"15","author":"F De Crescenzo","year":"2018","unstructured":"De Crescenzo F, et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis. PLoS Med. 2018;15(12): e1002715.","journal-title":"PLoS Med"},{"key":"976_CR100","doi-asserted-by":"crossref","unstructured":"Clay S et al. Perspectives and sentiments on contingency management from people who use methamphetamine. Drug and Alcohol Review, 2023","DOI":"10.1111\/dar.13691"},{"issue":"Suppl 1","key":"976_CR101","first-page":"i120","volume":"82","author":"TL Patterson","year":"2005","unstructured":"Patterson TL, et al. Methamphetamine-using HIV-positive men who have sex with men: correlates of polydrug use. J Urban Health Bull New York Academy Med. 2005;82(Suppl 1):i120\u20136.","journal-title":"J Urban Health Bull New York Academy Med"},{"issue":"8","key":"976_CR102","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/01.olq.0000258339.17325.93","volume":"34","author":"HH Spindler","year":"2007","unstructured":"Spindler HH, et al. Viagra, methamphetamine, and HIV risk: results from a probability sample of MSM. San Francisco Sexually transmitted diseases. 2007;34(8):586\u201391.","journal-title":"San Francisco Sexually transmitted diseases"},{"issue":"1","key":"976_CR103","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/QAI.0000000000001643","volume":"78","author":"JA Fulcher","year":"2018","unstructured":"Fulcher JA, et al. Brief report: recent methamphetamine use is associated with increased rectal mucosal inflammatory cytokines, regardless of HIV-1 serostatus. J Acquir Immune Deficiency Syndromes. 2018;78(1):119\u201323.","journal-title":"J Acquir Immune Deficiency Syndromes"},{"issue":"4","key":"976_CR104","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1080\/02791072.2016.1207826","volume":"48","author":"SG Mars","year":"2016","unstructured":"Mars SG, et al. The textures of heroin: User perspectives on \u201cblack tar\u201d and powder heroin in two US cities. J Psychoactive Drugs. 2016;48(4):270\u20138.","journal-title":"J Psychoactive Drugs"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00976-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-00976-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00976-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T09:06:50Z","timestamp":1709629610000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-00976-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["976"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-00976-1","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"22 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Daniel Ciccarone reports the following relevant financial relationships during the past 12 months: 1, he is a scientific advisor to Celero Systems and 2, he has been retained as an expert witness in ongoing prescription opioid litigation by Motley Rice, LLP. The remaining authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval for the study protocol was given by the Committee on Human Research at the University of California, San Francisco in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study and, where quotations have been used, for these to be published in a journal article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"57"}}